The aim of the study was to assess the changes in plasma lignocaine concentrations over time when the tumescent solution is injected into subcutaneous tissue of children undergoing surgical treatment of burns. Sixteen consecutive children with burns were studied using a prospective study design. After induction of general anesthesia, tumescent lignocaine solution 0.1% with adrenaline in nine patients (adrenaline group) for the treatment of postburn sequelae, or without adrenaline in seven patients (no-adrenaline group) for the treatment of acute burns, was injected into the subcutaneous tissue of burned and donor areas. The maximum dose of lignocaine was 7 mg/kg. Blood samples were collected before the start of the injection as well as at 5, 10, 20, 30, 45, 60, 90 minutes and 2, 4, 8, 12, 24 hours after the infiltration was completed. The course of lignocaine plasma levels was chaotic in the adrenaline group and biphasic during the first hour in the no-adrenaline group. The maximum plasma concentration of lignocaine was 2.09 µg/ml in the adrenaline group and 1.98 µg/ml in the no-adrenaline group. No adverse reactions were noted. Tumescent injection in burned children resulted in lignocaine plasma concentrations that were always lower than the often quoted value of 5 µg/ml, considered to be the toxic plasma threshold in adults. These data lend support to the use of lignocaine using the tumescent technique in burned paediatric patients.
The main concern when using regional or local anaesthesia during surgery is to obtain maximal local anaesthetic action with minimal systemic exposure. Tumescent local anaesthesia (TLA) is a technique based upon the direct infiltration of large volumes of a dilute solution of lignocaine into the subcutaneous fat, obtaining anaesthesia over wide areas of the skin and the subcutaneous tissue. TLA appears to be a safe method of regional anaesthesia for liposuction 1 , with respect to lignocaine absorption and toxicity [2] [3] [4] [5] [6] .
TLA technique has sparked more and more interest because of the specific advantages associated with its use, mainly low blood loss 8 and prolonged postoperative analgesia 3, 8 .
TLA combined with general anaesthesia has been used in a paediatric population for the surgical treatment of burned areas, also non-contiguous, covering no more than 20% of body surface area 8 . In this study, a long duration of postoperative analgesia of up to 24 hours was reported.
The most widely used local anaesthetics for TLA are lignocaine and prilocaine, and the pharmacokinetics of these agents in TLA has already been investigated in a number of previous studies 3,4,9 . However, there are no studies on the pharmacokinetics of lignocaine after TLA in children.
The purpose of our study was to determine plasma concentrations of lignocaine in children undergoing TLA for the surgical treatment of burns and postburn sequelae, in order to assess: 1) the safety of TLA technique by measuring maximum plasma concentrations following a maximal dose of 7 ml/kg of 0.1% lignocaine, and 2) the ability to treat larger burned areas by increasing the dose of TLA solution.
MATERIALS AND METHODS
After approval of the District Ethics Committee of Meyer Children's Hospital in Florence, Italy, and obtaining written informed consent from each parent, 16 consecutive unpremedicated children with American Society of Anesthesiologists physical status I and II undergoing general anaesthesia and TLA for the surgical treatment of acute burns (superficial necrectomy by dermabrasion) or postburn sequelae (escharectomy, skin harvesting and autologous skin grafting) were enrolled in the study. The patients had not received local anaesthetics before surgery.
We excluded patients with the following: 1) heart disease, 2) history of local anaesthetic allergy, 3) renal failure, 4) total body surface area burn greater than 20% and 5) infection of the surgical site with associated systemic signs of infection.
General anaesthesia was induced by facemask with sevoflurane in 50% nitrous oxide/oxygen. A laryngeal mask airway or an endotracheal tube was introduced for airway maintenance. No muscle relaxants were used. General anaesthesia was maintained with 1.5% sevoflurane and nitrous oxide/ oxygen 50% with patients breathing spontaneously.
Monitoring included pulse oximetry, electrocardiography, respiratory rate, end-tidal carbon dioxide, blood pressure and urine output.
The tumescent anaesthetic solution was prepared with aseptic technique in the operating room by the same investigator within one hour of administration. The anaesthetic solution consisted of 0.1% (1.0 mg/ml) lignocaine with 10 mEq/l sodium bicarbonate and 1:1,000,000 adrenaline in lactated Ringer solution. Adrenaline was not added to the anaesthetic solution for procedures involving fingers or toes, penis, nose, ear, or as requested by surgeons, for superficial necrectomy by dermabrasion for the surgical treatment of acute burns so as to not conceal small sources of bleeding, which might reveal areas of vital tissue. Thus two groups of patients were studied: adrenaline group and a no-adrenaline group. The maximum dose of lignocaine was 7 mg/kg, with the volume of the solution chosen on the basis of size of the surgical site. After warming the solutions in an incubator set at 37°C, TLA was performed by a manual technique with only a syringe. Tumescent lignocaine solution was injected into the subcutaneous tissue of burned and donor areas.
Venous blood samples (1 to 1.5 ml) for the determination of lignocaine concentrations were drawn through a separate peripheral intravenous catheter (BD Intima 22 gauge, 0.9×19 mm, Becton Dickinson, Sandy, UT, USA) not used for intravenous fluid administration, before the start of the injection as well as at 5, 10, 20, 30, 45, 60, 90 minutes and 2, 4, 8, 12, 24 hours after the infiltration was completed. The samples were drawn without preservative and stored at 2°C until analysed. After each blood sample was taken, the intravenous catheter was flushed with heparinised saline. The lignocaine assays were performed within one hour of the sample being taken.
During the postoperative period, the occurrence of any sign of possible local anaesthetic toxicity, such as seizures, somnolence or restlessness, headache, dizziness and perioral or lingual paraesthesia, when the patients were old enough to report them, were noted by the nursing team.
In each sample, identified by barcode, serum was obtained by allowing the sample to come to room temperature long enough for clot retraction to take place and then by centrifuging the sample at 2.000 rpm. for 10 minutes. From each sample, 100 µl of serum was used for the assay.
The lignocaine assay was performed using Fluorescent Polarization Immunoassay technology (Analyser TDX Abbot) based on a competitive link between the anti-lignocaine antibody of rabbit and the serum lignocaine. The method is not influenced by haemoglobin up to 860 mg/dl and total bilirubin up to 15 mg/dl. Cross-reactivity was tested for compounds whose chemical structure or concurrent usage could cause potential interference with the lignocaine assay. Sensitivity, defined as the lowest measurable concentration which can be distinguished from zero with 95% confidence, was determined to be 0.10 µg/ml.
RESULTS
Demographic, surgical and monitoring data are reported as in Table 1 . Plasma lignocaine in the no-adrenaline group. Signs of toxicity did not occur in any patient.
DISCUSSION
It is well demonstrated that in adults undergoing TLA for liposuction surgery, peak blood and plasma concentrations are reached four to 14 hours after infiltration of lignocaine solutions 0.05 to 0.4% 3-5,10-12 and, with few exceptions 6 , peak plasma concentrations remain below of the value of 5 µg/ml, concentrations are shown in Figure 1 for the solution with adrenaline and in Figure 2 for the solution without adrenaline.
The course of lignocaine plasma concentrations was biphasic, with two peaks appearing within the first hour in the no-adrenaline group, while the course of plasma concentrations was unpredictable and chaotic in the adrenaline group.
Maximum plasma concentration of lignocaine was 2.09 µg/ml in the adrenaline group and 1.98 µg/ml generally considered to be the toxic threshold of lignocaine in adults. There are no data regarding the toxic thresholds of lignocaine in children, but it is usually thought that this value is the same as in adults. Some authors have reported concentrations higher than 5 µg/ml of lignocaine in children without clinical signs of toxicity, particularly in the neonate 13 . Low systemic availability has been observed after infiltration of large doses of lignocaine using TLA in adults 3, 4, 11 . High dilution of the lignocaine solution, low tissue perfusion and the addition of a vasoconstrictor may explain the low plasma concentrations of lignocaine, despite the large doses that were utilised. The present study is, to the best of our knowledge, the first to investigate the pharmacokinetic characteristics of lignocaine after TLA in children with burns. In a population of 14 children with acute burns requiring skin grafts, Fischer et al 14 established that the infiltration of bupivacainecontaining solution into the donor site at a dose of slightly less than 1.9 mg/kg is safe, as demonstrated by low plasma levels (maximum mean plasma levels 0.39±0.09 µg/ml and highest level 1.2 µg/ml) and the absence of clinical signs of toxicity.
In this study, only total lignocaine concentrations were measured. Only free lignocaine is toxic. The free fraction observed in children older than one year is similar to that measured in adults 15 . Lignocaine binds mainly to α1-acid glycoprotein and also to human serum albumin. In burned patients, albumin levels may be significantly lower than normal, with a subsequent increase of free lignocaine. This aspect could lead to underestimation of the real threshold for lignocaine toxicity. However, α1-acid glycoprotein is a major acute phase protein.
Its concentration rapidly and significantly increases when inflammatory processes develop, including during the postoperative period, compared with preoperative values 16, 17 . This increase results in a rapid decrease in the free fraction during the first three to six hours following surgery 17 . Thus it is hard to predict the concentration of free lignocaine for any given total concentration, given these two opposite influences on the quantity of bound and unbound drug.
The chaotic lignocaine plasma concentrations in the adrenaline group may be a consequence of the variable and non-uniform tissue changes, including fibrosis and necrosis which are typical of a tissue with chronic inflammation, as is the case of post-burn sequelae. On the other hand, the use of the solution without adrenaline for acute burns may be due to the absence of tissue changes as mentioned above.
Miyabe et al 18 demonstrated that the addition of adrenaline to lignocaine for continuous epidural infusion in children does not reduce the plasma concentration. In our study, similar results were found. However, even though the use of adrenaline does not significantly reduce peak plasma concentrations of lignocaine and the appearance of the peak concentrations is unpredictable within the first four hours, we cannot imply that plain lignocaine is better in these circumstances, because lignocaine with adrenaline was used in patients at a later time after their injuries. We cannot state whether there would be a difference between the peak drug concentrations obtained with adrenaline containing or non-adrenaline containing solutions when used in a paediatric population without burn injuries.
Dosages of lignocaine utilised for conventional local and regional anaesthetic techniques also appear safe for TLA in children with burns, because plasma concentrations of lignocaine have always been below 5 µg/ml. In our study, the maximum lignocaine plasma concentration was 2.09 µg/ml and this could be the basis for further studies on the use of even higher doses in children and allowing the opportunity to treat burns of greater than 20% body surface area.
We are aware that our study presents some limitations. Plasma lignocaine concentrations may be affected by several variables: 1) the anatomic site of TLA (burned or donor skin), since it is not known if tissue perfusion in burned areas is higher, lower or the same as in donor areas, and thus affect the systemic uptake of lignocaine from the subcutaneous space; 2) the total dose of lignocaine administered, depending on the percent of body surface the burned; 3) the variable cardiac output seen over time in burn patients, since variations in patients' cardiac output may affect hepatic clearance of lignocaine 19 .
Despite these limitations, this study seems to support the use of lignocaine in a dose up to 7 mg/kg employing the tumescent technique in children with burns.
